-
公开(公告)号:US20070093475A1
公开(公告)日:2007-04-26
申请号:US11634788
申请日:2006-12-05
申请人: Paul Feldman , David Jung , Istvan Kaldor , Gregory Pacofsky , Jeffrey Stafford , Jeffrey Tidwell
发明人: Paul Feldman , David Jung , Istvan Kaldor , Gregory Pacofsky , Jeffrey Stafford , Jeffrey Tidwell
IPC分类号: A61K31/5513 , C07D403/02 , C07D243/14
CPC分类号: C07D243/20 , C07D401/04 , C07D401/12 , C07D403/12 , C07D487/04
摘要: The present invention provides a compound of formula (I): wherein all variables are as defined herein, pharmaceutical formulations containing the same, processes for preparing the same and their use therapy.
摘要翻译: 本发明提供式(I)化合物:其中所有变量如本文所定义,含有该化合物的药物制剂,其制备方法及其使用疗法。
-
公开(公告)号:US20050288515A1
公开(公告)日:2005-12-29
申请号:US10530810
申请日:2003-10-10
申请人: Matthew Brown , Mui Cheung , Scott, Howard Dickerson , Cassandra Gauthier , Philip, Anthony Harris , Robert, Neil Hunter , Gregory Pacofsky , Michael, Robert Peel , Jeffrey, Alan Stafford
发明人: Matthew Brown , Mui Cheung , Scott, Howard Dickerson , Cassandra Gauthier , Philip, Anthony Harris , Robert, Neil Hunter , Gregory Pacofsky , Michael, Robert Peel , Jeffrey, Alan Stafford
IPC分类号: A61K20060101 , A61K31/421 , A61K31/422 , C07D263/30 , C07D263/48 , C07D413/02 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/10 , C07D417/12
CPC分类号: C07D263/48 , C07D413/04 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/10 , C07D417/12
摘要: Oxazole derivatives, which are useful as VEGFR2, CDK2, and CDK4 inhibitors are described herein. The described invention also includes methods of making such oxazole derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.
摘要翻译: 本文描述了可用作VEGFR2,CDK2和CDK4抑制剂的恶唑衍生物。 所述的发明还包括制备这种恶唑衍生物的方法以及使用它们在治疗过度增殖性疾病中的方法。
-
公开(公告)号:US07189712B2
公开(公告)日:2007-03-13
申请号:US10530810
申请日:2003-10-10
申请人: Matthew Lee Brown , Mui Cheung , Scott Howard Dickerson , Cassandra Gauthier , Philip Anthony Harris , Robert Neil Hunter , Gregory Pacofsky , Michael Robert Peel , Jeffrey Alan Stafford
发明人: Matthew Lee Brown , Mui Cheung , Scott Howard Dickerson , Cassandra Gauthier , Philip Anthony Harris , Robert Neil Hunter , Gregory Pacofsky , Michael Robert Peel , Jeffrey Alan Stafford
IPC分类号: A61K31/541 , A61K31/5355 , A61K31/496 , A61K31/4525 , A61K31/443 , A61K31/421 , C07D417/10 , C07D413/10
CPC分类号: C07D263/48 , C07D413/04 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/10 , C07D417/12
摘要: Oxazole derivatives, which are useful as VEGFR2, CDK2, and CDK4 inhibitors are described herein. The described invention also includes methods of making such oxazole derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.
摘要翻译: 本文描述了可用作VEGFR2,CDK2和CDK4抑制剂的恶唑衍生物。 所述的发明还包括制备这种恶唑衍生物的方法以及使用它们在治疗过度增殖性疾病中的方法。
-
公开(公告)号:US20070173504A1
公开(公告)日:2007-07-26
申请号:US11613872
申请日:2006-12-20
申请人: Gregory Pacofsky , Mark Suto , Paul Fritch
发明人: Gregory Pacofsky , Mark Suto , Paul Fritch
IPC分类号: A61K31/53 , A61K31/506 , C07D417/02
CPC分类号: C07D277/54 , C07D277/46 , C07D277/48 , C07D417/12 , C07D417/14
摘要: The present invention provides novel calcium channel antagonists, and methods of treating disease sates using the novel antagonists.
-
公开(公告)号:US20070135419A1
公开(公告)日:2007-06-14
申请号:US11650635
申请日:2007-01-05
申请人: Paul Feldman , David Jung , Istvan Kaldor , Gregory Pacofsky , Jeffrey Stafford , Jeffrey Tidwell
发明人: Paul Feldman , David Jung , Istvan Kaldor , Gregory Pacofsky , Jeffrey Stafford , Jeffrey Tidwell
IPC分类号: A61K31/5513 , C07D243/14
CPC分类号: C07D243/20 , C07D401/04 , C07D401/12 , C07D403/12 , C07D487/04
摘要: The present invention provides a compound of formula (I): wherein all variables are as defined herein, pharmaceutical formulations containing the same, processes for preparing the same and their use therapy.
-
6.
公开(公告)号:US5416089A
公开(公告)日:1995-05-16
申请号:US80862
申请日:1993-06-24
申请人: Arthur D. Patten , Gregory Pacofsky , Steven P. Seitz , Emeka A. Akamike , Robert J. Cherney , Robert F. Kaltenbach, III , Michael J. Orwat
发明人: Arthur D. Patten , Gregory Pacofsky , Steven P. Seitz , Emeka A. Akamike , Robert J. Cherney , Robert F. Kaltenbach, III , Michael J. Orwat
IPC分类号: A61K31/435 , A61P35/00 , C07D221/18 , C07D471/06 , C07D491/06 , C07D495/06 , C07D498/06 , C07D513/06 , A61K31/47
CPC分类号: C07D471/06 , C07D221/18 , C07D491/06 , C07D495/06 , C07D513/06
摘要: Anticancer compounds of formula I: ##STR1## and pharmaceutically acceptable salts thereof, wherein: R.sup.1, R.sup.2 and R.sup.3 are independently selected H, CH.sub.3, NH.sub.2, NO.sub.2, and CN;R.sup.9 and R.sup.10 are H or alkyl or halo, X.sup.1 and Y.sup.1 or X.sup.2 and Y.sup.2, when present, join together to form, independently, a six membered 1N heterocycle substituted with 1-2 R.sup.3 ; or the group: ##STR2## wherein one of W or Z is C.dbd.O and the other is C.dbd.O, NH, S or O; or when X.sup.2 and Y.sup.2 are not joined together and when R.sup.2 is in the 4-position, then X.sup.2 and R.sup.2 may join together to form an ethylene bridge; are disclosed.
摘要翻译: 式I的抗癌化合物:其中R 1,R 2和R 3独立地选自H,CH 3,NH 2,NO 2和CN; 当R 9和R 10为H或烷基或卤素时,X 1和Y 1或X 2和Y 2存在时,连接在一起以独立地形成被1-2个R 3取代的六元元素的杂环; 或者组成:其中W或Z之一为C = O,另一个为C = O,NH,S或O; 或当X2和Y2不连接在一起时,当R2为4-位时,则X2和R2可以连接在一起形成乙烯桥; 被披露。
-
公开(公告)号:US20070135421A1
公开(公告)日:2007-06-14
申请号:US11650637
申请日:2007-01-05
申请人: Paul Feldman , David Jung , Istvan Kaldor , Gregory Pacofsky , Jeffrey Stafford , Jeffrey Tidwell
发明人: Paul Feldman , David Jung , Istvan Kaldor , Gregory Pacofsky , Jeffrey Stafford , Jeffrey Tidwell
IPC分类号: A61K31/5513 , C07D403/02 , C07D243/14
CPC分类号: C07D243/20 , C07D401/04 , C07D401/12 , C07D403/12 , C07D487/04
摘要: The present invention provides a compound of formula (I): wherein all variables are as defined herein, pharmaceutical formulations containing the same, processes for preparing the same and their use therapy.
-
8.
公开(公告)号:US5585382A
公开(公告)日:1996-12-17
申请号:US392018
申请日:1995-02-21
申请人: Arthur D. Patten , Gregory Pacofsky , Steven P. Seitz , Emeka A. Akamike , Robert J. Cherney , Robert F. Kaltenbach, III , Michael J. Orwat
发明人: Arthur D. Patten , Gregory Pacofsky , Steven P. Seitz , Emeka A. Akamike , Robert J. Cherney , Robert F. Kaltenbach, III , Michael J. Orwat
IPC分类号: A61K31/435 , A61P35/00 , C07D221/18 , C07D471/06 , C07D491/06 , C07D495/06 , C07D498/06 , C07D513/06 , A61K31/47
CPC分类号: C07D471/06 , C07D221/18 , C07D491/06 , C07D495/06 , C07D513/06
摘要: Anticancer compounds of formula I: ##STR1## and pharmaceutically acceptable salts thereof, wherein: R.sup.1, R.sup.2, R.sup.3, R.sup.9 and R.sup.10 are independently selected from the group H, C.sub.1 -C.sub.4 alkyl, OR.sup.4, N(R.sup.4).sub.2, NO.sub.2, CN, F, Cl, Br, I, Ph, and CF.sub.3, and NHC(O)R.sup.4 ;R.sup.4 is independently selected from the group H, C.sub.1 -C.sub.4 alkyl, Ph, and CH.sub.2 Ph;X.sup.1 and Y.sup.1, and X.sup.2 and Y.sup.2 when present, join together to form:a benzene ring substituted with 1-4 R.sup.3 ;a five membered heterocycle having 1-2N, NH, O or S atoms and substituted with 1-2 R.sup.3 ;a six membered heterocycle having 1-2N and substituted with 1-2 R.sup.3 ; orthe group: ##STR2## wherein one of W or Z is C.dbd.O and the other is C.dbd.O, NH, S or O; or when X.sup.2 and Y.sup.2 are present and not joined together and when R.sup.2 is in the 4-position, then X.sup.2 and R.sup.2 may join together to form an ethylene bridge;are addressed.
摘要翻译: 式I的抗癌化合物:其中:R1,R2,R3,R9和R10独立地选自H,C1-C4烷基,OR4,N(R4)2, NO2,CN,F,Cl,Br,I,Ph和CF3,NHC(O)R4; R 4独立地选自H,C 1 -C 4烷基,Ph和CH 2 Ph; X1和Y1,X2和Y2存在时,连接在一起形成:被1-4个R3取代的苯环; 具有1-2N,NH,O或S原子并被1-2个R 3取代的五元杂环; 具有1-2N并被1-2个R 3取代的六元杂环; 或者组成:其中W或Z之一为C = O,另一个为C = O,NH,S或O; 或当X2和Y2存在并且不连接在一起时,当R2在4-位时,则X2和R2可以连接在一起形成乙烯桥; 被解决。
-
9.
公开(公告)号:US20140142114A1
公开(公告)日:2014-05-22
申请号:US14083879
申请日:2013-11-19
申请人: Charles Q. Meng , Alan Long , Scot Huber , Srinivas Reddy Gurrala , Douglas Edward Wilkinson , Gregory Pacofsky
发明人: Charles Q. Meng , Alan Long , Scot Huber , Srinivas Reddy Gurrala , Douglas Edward Wilkinson , Gregory Pacofsky
IPC分类号: C07D215/38 , A61K31/495 , A61K31/4995 , A61K31/4704 , A61K31/167 , C07D401/06 , C07D307/81 , C07D241/04 , C07D471/08 , C07C237/22 , A61K45/06 , C07D401/12 , C07D277/64 , C07D417/06 , A61K31/496
CPC分类号: C07D215/38 , A61K31/167 , A61K31/47 , A61K31/4704 , A61K31/472 , A61K31/495 , A61K31/496 , A61K31/4995 , A61K45/06 , C07C233/56 , C07C235/16 , C07C2601/14 , C07D211/58 , C07D213/74 , C07D215/42 , C07D217/06 , C07D241/04 , C07D263/58 , C07D277/64 , C07D277/82 , C07D295/15 , C07D295/16 , C07D295/185 , C07D295/215 , C07D307/14 , C07D307/81 , C07D307/82 , C07D333/60 , C07D333/66 , C07D401/06 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/06 , C07D417/12 , C07D471/08
摘要: The present invention relates to novel anthelmintic compounds of formula (I) below: wherein Y and Z are independently a bicyclic carbocyclic or a bicyclic heterocyclic group, or one of Y or Z is a bicyclic carbocyclic or a bicyclic heterocyclic group and the other of Y or Z is alkyl, alkenyl, alkynyl, cycloalkyl, phenyl, heterocyclyl or heteroaryl, and variables X1, X2, X3, X4, X5, X6, X7 and X8 are as defined herein. The invention also provides for veterinary compositions comprising the anthelmintic compounds of the invention, and their uses for the treatment and prevention of parasitic infections in animals.
摘要翻译: 本发明涉及以下式(I)的新型驱肠剂化合物:其中Y和Z独立地为双环碳环或双环杂环基,或Y或Z中的一个为双环碳环或双环杂环基,Y中的另一个为 或Z是烷基,烯基,炔基,环烷基,苯基,杂环基或杂芳基,变量X1,X2,X3,X4,X5,X6,X7和X8如本文所定义。 本发明还提供包含本发明的驱肠剂化合物的兽用组合物及其用于治疗和预防动物寄生虫感染的用途。
-
公开(公告)号:US20070197523A1
公开(公告)日:2007-08-23
申请号:US11613950
申请日:2006-12-20
申请人: Gregory Pacofsky , Mark Suto , Paul Fritch
发明人: Gregory Pacofsky , Mark Suto , Paul Fritch
IPC分类号: A61K31/535 , A61K31/415 , C07D239/02 , C07D265/28 , A61K31/426
CPC分类号: C07D417/12 , C07D277/28 , C07D277/34 , C07D277/36 , C07D277/46 , C07D277/54 , C07D277/56 , C07D413/04 , C07D417/04 , C07D417/14
摘要: The present invention provides novel calcium channel antagonists, and methods of treating disease sates using the novel antagonists.
摘要翻译: 本发明提供新型钙通道拮抗剂,以及使用新型拮抗剂治疗疾病的方法。
-
-
-
-
-
-
-
-
-